Triple
T3849410
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Center for Drug Evaluation and Research |
E85252
|
entity |
| Predicate | oversees |
P46
|
FINISHED |
| Object |
Office of Generic Drugs
The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and high quality.
|
E85252
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of Generic Drugs | Statement: [Center for Drug Evaluation and Research, oversees, Office of Generic Drugs]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Office of Generic Drugs Context triple: [Center for Drug Evaluation and Research, oversees, Office of Generic Drugs]
-
A.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
B.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
C.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
D.
Food and Drug Administration
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
-
E.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Office of Generic Drugs Triple: [Center for Drug Evaluation and Research, oversees, Office of Generic Drugs]
Generated description
The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and high quality.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Office of Generic Drugs Target entity description: The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and high quality.
-
A.
Center for Drug Evaluation and Research
chosen
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
B.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
C.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
D.
Food and Drug Administration
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
-
E.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
- F. None of above.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69aed936de1c81908f91bed80f70abb2 |
completed | March 9, 2026, 2:29 p.m. |
| NER | Named-entity recognition | batch_69aeebcde86081908cf3840ae002acfa |
completed | March 9, 2026, 3:48 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69b504172d58819089d19f5cb7b803ec |
completed | March 14, 2026, 6:45 a.m. |
| NEDg | Description generation | batch_69b504f32da48190a561cc72f0c4e827 |
completed | March 14, 2026, 6:49 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69b5064192a48190a0f95dee872437e0 |
completed | March 14, 2026, 6:54 a.m. |
Created at: March 9, 2026, 3:19 p.m.